We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 397

Expanded Scope of the Physician Sunshine Act Is on the Horizon
  • Arent Fox LLP
  • USA
  • October 16 2018

Existing law already requires drug manufacturers and medical device companies to report certain payments and transfers of value provided to

Escobar The Sequel? Perhaps Coming Soon to SCOTUS
  • Vinson & Elkins LLP
  • USA
  • April 19 2018

On April 16, 2018, the Supreme Court called for the views of the Solicitor General (or “CVSG”) as to whether it should review the Ninth Circuit’s

2016 False Claims Act Review: A Truly Extraordinary Year
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • April 1 2017

As we head into the second quarter of an already turbulent 2017, it is worth reflecting on the truly extraordinary events of 2016. Of course, there

Another Jury Acquits in One of the First Few Prosecutions of Health Care Executives Following DOJ’s Yates Memo
  • Mintz
  • USA
  • July 27 2016

Last month, we reported on a Massachusetts federal court jury’s decision to acquit the former CEO of Warner Chilcott in one of the first prosecutions

CMS Proposes Revamp to Medicare Part B Drug Reimbursement in Two Phases
  • FisherBroyles LLP
  • USA
  • March 11 2016

The Centers for Medicare and Medicaid Services ("CMS") announced a proposed rule (CMS-1670-P) to test new models to improve how Medicare Part B pays

Medicaid Drug Rebate Program: CMS releases final covered outpatient drug regulation
  • Hogan Lovells
  • USA
  • January 28 2016

The Centers for Medicare & Medicaid Services (CMS) released the final Medicaid covered outpatient drug regulation on Thursday, January 21, 2016. The

Pros and Cons of Drug Price Renegotiation
  • Han Kun Law Offices
  • China
  • December 31 2015

The issue of second-round drug price negotiations following centralized procurement ("Price Renegotiation") was bound to be controversial from the

Drug and alcohol testing at work doesn’t deter anyone, so why do it?
  • HopgoodGanim
  • Australia
  • December 14 2015

All Australian government-funded construction sites now require contractors to have a comprehensive fitness-for-work policy that includes mandatory

OIG approves limited, free drug program
  • Ober Kaler
  • USA
  • August 28 2015

On August 12, 2015, the Department of Health and Human Services, Office of Inspector General (OIG) issued Advisory Opinion 15-11, approving two

Off-label marketing and the False Claims Act
  • Mintz
  • USA
  • August 21 2015

In a post published earlier this week this week our colleagues Brian Dunphy and Joanne Hawana examined key issues in the recent Amarin decision from